Oral Session

Oral Session 2-8B Condtioning regimens for transplant

Sat. Oct 13, 2018 10:10 AM - 11:10 AM No.8 (Osaka International Convention Center, 10F 1002)

Chair: Junichi Sugita (Hokkaido University Hospital Department of Hematology, Japan)

+Add all to schedule

[OS2-8B-1] Efficacy and safety of low-dose antithymocyte globulin (ATG) in HLA mismatced unrelated HSCT

Shihomi Taniyama, Hirofumi Yokota, Yuki Takeuchi, Hitomi Sawa, Kanae Imai, Yuichiro Inagaki, Tomonori Kato, Masashi Sawa (Hematology and oncology, Anjo Kosei Hosp., Aichi, Japan)

[OS2-8B-2] ATG with MAC improved moderate or severe cGVHD-free+relapse-free survival, 50 patients

Yuki Takeuchi, Hirofumi Yokota, Shihomi Taniyama, Hitomi Sawa, Kanae Imai, Yuichiro Inagaki, Tomonori Kato, Masashi Sawa (Department of Hematology and Oncology, Anjo Kosei Hospital)

[OS2-8B-3] Impact of low-dose ATG on immune reconstitution after allogeneic hematopoietic cell transplantation

Ayumu Ito¹, Shigehisa Kitano², Kinuko Tajima¹, Kyosuke Yamaguchi¹, Masatomo Kuno¹, Takashi Tanaka¹, Yoshihiro Inamoto¹, Saiko Kurosawa¹, Sung-Won Kim¹, Takahiro Fukuda¹ (1.Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan, 2.Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan)

[OS2-8B-4] Association of ATG ratio (blood cell count/total dose of ATG) with outcomes after allogeneic HCT

Kyosuke Yamaguchi, Yoshihiro Inamoto, Kinuko Tajima, Masatomo Kuno, Takashi Tanaka, Ayumu Ito, Saiko Kurosawa, Sung-Won Kim, Takahiro Fukuda (Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital , Tokyo, Japan)

[OS2-8B-5] Impact of low-dose irradiation and TCD in HSCT against non-malignant diseases using a RIC

Katsutsugu Umeda¹, Hiromasa Yabe², Koji Kato³, Kousuke Imai⁴, Masao Kobayashi⁵, Yoshiyuki Takahashi⁶, Masami Inoue⁷, Yoshiko Hashii⁸, Yoshiko Atsuta⁹, Tomohiro Morio⁴ (1.Dept. Pediatrics, Kyoto University, Kyoto, Japan, 2.Dept. Cell Transplantation and Regenerative Medicine, Tokai University, Isehara, Japan, 3.Dept. Hematol/Oncol, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, 4.Dept. Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan, 5.Dept.Pediatrics, Hiroshima University, Hiroshima, Japan, 6.Dept. Pediatrics, Nagoya University, Nagoya, Japan, 7.Dept. Hematology/Oncology, Osaka Medical Center and Research Institute, Izumi, Japan, 8.Dept. Pediatrics, Osaka University, Suita, Japan, 9.Japanese Data Center for Hematopoietic Cell, Nagoya, Japan)

[OS2-8B-6] Fludarabine/Melphalan/4-Gy TBI followed by umbilical cord blood transplantation for aplastic anemia

Hideo Koh¹, Takuro Yoshimura^1,2, Yumi Tagaito¹, Tetsuya Hayashi¹, Naonori Harada¹, Hiroshi Okamura¹, Satoru Nanno¹, Asao Hirose¹, Mika Nakamae¹, Yasuhiro Nakashima¹, Takahiko Nakane¹, Masayuki Hino¹, Hirohisa Nakamae¹ (1.Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan, 2.Department of Hematology, Osaka City General Hospital, Osaka, Japan)